{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:06:21Z","timestamp":1760299581227,"version":"3.41.2"},"reference-count":23,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2017.00226","type":"journal-article","created":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T14:08:44Z","timestamp":1493215724000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Sodium 4-Carboxymethoxyimino-(4-HPR) a Novel Water-Soluble Derivative of 4-Oxo-4-HPR Endowed with In Vivo Anticancer Activity on Solid Tumors"],"prefix":"10.3389","volume":"8","author":[{"given":"Paola","family":"Tiberio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Cavadini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loredana","family":"Cleris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Dallavalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loana","family":"Musso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria G.","family":"Daidone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Appierto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2017,4,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1158\/1535-7163","article-title":"Antimitotic effect of the retinoid 4-oxo-fenretinide through inhibition of tubulin polymerization: a novel mechanism of retinoid growth-inhibitory activity.","volume":"8","author":"Appierto","year":"","journal-title":"Mol. Cancer Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/carcin\/bgp067","article-title":"PLAB induction in fenretinide-induced apoptosis of ovarian cancer cells occurs via a ROS-dependent mechanism involving ER stress and JNK activation.","volume":"30","author":"Appierto","year":"","journal-title":"Carcinogenesis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/sj.cdd.4401349","article-title":"Involvement of c-Fos in fenretinide-induced apoptosis in human ovarian carcinoma cells.","volume":"11","author":"Appierto","year":"2004","journal-title":"Cell Death Differ."},{"key":"B4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0014-5793(04)00173-5","article-title":"The nitration of tau protein in neuron-like PC12 cells.","volume":"562","author":"Cappelletti","year":"2004","journal-title":"FEBS Lett."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/172897","article-title":"Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?","volume":"2012","author":"Cazzaniga","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/ijc.20923","article-title":"Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results.","volume":"115","author":"Chiesa","year":"2005","journal-title":"Int. J. Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.critrevonc.2015.04.011","article-title":"Taxane induced neuropathy in patients affected by breast cancer: literature review.","volume":"96","author":"De Iuliis","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1006\/gyno.2002.6663","article-title":"Effect of fenretinide on ovarian carcinoma occurrence.","volume":"86","author":"De Palo","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0749-2081(03)00059-7","article-title":"Prevention and treatment of adverse effects related to chemotherapy for recurrent ovarian cancer.","volume":"19","author":"Edwards","year":"2003","journal-title":"Semin. Oncol. Nurs."},{"key":"B10","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00520-002-0405-9","article-title":"Managing taxane toxicities.","volume":"11","author":"Markman","year":"2003","journal-title":"Support Care Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1158\/1535-7163.MCT-08-0840","article-title":"Platinum neurotoxicity pharmacogenetics.","volume":"8","author":"McWhinney","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1471::AID-CNCR1>3.0.CO;2-6","article-title":"The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer.","volume":"83","author":"Miller","year":"1998","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0304-3835(96)04475-8","article-title":"Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses.","volume":"110","author":"Moglia","year":"1996","journal-title":"Cancer Lett."},{"key":"B14","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/cbdd.12781","article-title":"Water-soluble derivatives of 4-oxo-N-(4-hydroxyphenyl) retinamide: synthesis and biological activity.","volume":"88","author":"Musso","year":"2016","journal-title":"Chem. Biol. Drug Des."},{"key":"B15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/sj.cdd.4400337","article-title":"Retinoid-induced apoptosis in normal and neoplastic tissues.","volume":"5","author":"Nagy","year":"1998","journal-title":"Cell Death Differ."},{"key":"B16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/oxfordjournals.jncimonographs.a003451","article-title":"Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer.","volume":"30","author":"Partridge","year":"2001","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013362","article-title":"4-oxo-N-(4-hydroxyphenyl)retinamide: two independent ways to kill cancer cells.","volume":"5","author":"Tiberio","year":"2010","journal-title":"PLoS ONE"},{"key":"B18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0304-3835(94)90385-9","article-title":"Successful topical treatment of oral lichen planus and leukoplakias with fenretinide (4-HPR).","volume":"76","author":"Tradati","year":"1994","journal-title":"Cancer Lett."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1093\/annonc\/mdl047","article-title":"Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer.","volume":"17","author":"Veronesi","year":"2006","journal-title":"Ann. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1158\/0008-5472.CAN-05-3362","article-title":"4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.","volume":"66","author":"Villani","year":"2006","journal-title":"Cancer Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"6265","DOI":"10.1158\/1078-0432.CCR-04-0655","article-title":"Identification of the fenretinide metabolite 4-oxo-fenretinide present in human plasma and formed in human ovarian carcinoma cells through induction of cytochrome P450 26A1.","volume":"10","author":"Villani","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"B22","first-page":"453","article-title":"Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma.","volume":"29","author":"Zaffaroni","year":"2007","journal-title":"Cell. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1677\/erc.1.00938","article-title":"Clinical trials with retinoids for breast cancer chemoprevention.","volume":"13","author":"Zanardi","year":"2006","journal-title":"Endocr. Relat. Cancer"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00226\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T09:20:05Z","timestamp":1601976005000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00226\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,26]]},"references-count":23,"alternative-id":["10.3389\/fphar.2017.00226"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2017.00226","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2017,4,26]]},"article-number":"226"}}